Patents by Inventor Shammana N. Muddukrishna

Shammana N. Muddukrishna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents

Patent number: 10800820

Abstract: The present invention relates to the provision of a biologically safe hemolymph sera, preferably hemocyanin, more preferably KLH (keyhole limpet hemocyanin). The hemocyanin is purified using anion exchange chromatography.

Type: Grant

Filed: June 12, 2014

Date of Patent: October 13, 2020

Assignee: Biosyn Arzneimittel GmbH

Inventors: Ortwin Kottwitz, Thomas Stiefel, Shammana N. Muddukrishna
Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents

Patent number: 10221220

Abstract: The present invention relates to the provision of a biologically safe hemolymph sera, preferably hemocyanin, more preferably KLH (keyhole limpet hemocyanin). A method for producing virus free hemocyanin is provided.

Type: Grant

Filed: June 12, 2014

Date of Patent: March 5, 2019

Assignee: biosyn Arzneimittel GmbH

Inventors: Ortwin Kottwitz, Thomas Stiefel, Shammana N. Muddukrishna
Preparation Methods for a Novel Generation of Biological Safe KLH Products Used for Cancer Treatment, for the Development of Conjugated Therapeutic Vaccines and as Challenging Agents

Publication number: 20170129928

Abstract: The present invention relates to the provision of a biologically safe hemolymph sera, preferably hemocyanin, more preferably KLH (keyhole limpet hemocyanin). A method for producing virus free hemocyanin is provided.

Type: Application

Filed: June 12, 2014

Publication date: May 11, 2017

Applicant: Biosyn Arzneimittel GmbH

Inventors: Ortwin Kottwitz, Thomas Stiefel, Shammana N. Muddukrishna
Preparation Methods for a Novel Generation of Biological Safe KLH Products Used for Cancer Treatment, for the Development of Conjugated Therapeutic Vaccines and as Challenging Agents

Publication number: 20170121376

Abstract: The present invention relates to the provision of a biologically safe hemolymph sera, preferably hemocyanin, more preferably KLH (keyhole limpet hemocyanin). The hemocyanin is purified using anion exchange chromatography.

Type: Application

Filed: June 12, 2014

Publication date: May 4, 2017

Applicant: Biosyn Arzneimittel GmbH

Inventors: Ortwin Kottwitz, Thomas Stiefel, Shammana N. Muddukrishna

Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents

Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents

Preparation Methods for a Novel Generation of Biological Safe KLH Products Used for Cancer Treatment, for the Development of Conjugated Therapeutic Vaccines and as Challenging Agents

Preparation Methods for a Novel Generation of Biological Safe KLH Products Used for Cancer Treatment, for the Development of Conjugated Therapeutic Vaccines and as Challenging Agents